Cell-free bone scaffolds that present the chemokine SDF-1α (stromal cell-derived factor-1α) can recruit endogenous mesenchymal stem/stromal cells (MSCs) and regenerate segmental bone defects without cell transplantation, as demonstrated by Chen and Lv (Scientific Reports, 2017) using an elasticity-modified decellularized bone scaffold. That study, and the literature that followed it, leaves a precise open core with three linked components: (1) the in vivo cellular origin of the recruited MSC-like cells — local tissue-resident progenitors, circulating bone-marrow-derived cells, or other niches — has never been determined by fate-mapping or comparable direct methods in the scaffold-recruitment context; (2) the temporal decline of recruited-cell density observed as scaffold chemokine release wanes means that potentiated, prolonged presentation sustaining recruitment, rather than letting it decline with waning release, remains a general open design challenge; (3) the mechanisms underlying the observed transient macrophage response and enhanced CD34-positive vessel formation on the scaffold are not established — the source offers only explicitly speculative explanations. Together these questions decide whether endogenous-cell recruitment can become a mechanistically understood, controllable substitute for stem-cell transplantation in bone regeneration.

Background

In situ tissue engineering is a regenerative-medicine strategy that avoids transplanting expanded cells: an implanted biomaterial releases chemoattractant signals that recruit the body's own stem and progenitor cells to the defect site and provides physical and molecular cues that direct their differentiation. A central chemokine for this approach is stromal cell-derived factor-1α (SDF-1α, also called CXCL12), which binds the G-protein-coupled receptor CXCR4 on mesenchymal stem/stromal cells (MSCs, multipotent cells marked in vivo by surface proteins such as CD29, CD44, CD90, and CD105) and on endothelial and hematopoietic progenitors, guiding their migration to injured tissue. Chen and Lv (Scientific Reports 7:1672, 2017) built a scaffold in this spirit: decellularized bone matrix (bone stripped of its cells, retaining the extracellular matrix and intrinsic growth factors such as BMP-2, bone morphogenetic protein 2, an osteogenic growth factor) coated with a collagen/hydroxyapatite (Col/HA) mixture chosen so that the matrix elasticity (Young's modulus about 23.6 kPa) favors osteogenic differentiation of MSCs, and loaded with SDF-1α. In vitro, MSC adhesion, growth, and osteogenic differentiation (osteopontin and osteocalcin expression, i.e. bone-matrix proteins produced as cells commit to the osteoblast lineage, and extracellular matrix deposition) were enhanced by the combination of matrix elasticity and SDF-1α. In rat subcutaneous implants, recruited cells positive for MSC markers accumulated far more in the SDF-1α/Col/HA scaffold than in uncoated or Col/HA-only controls, peaking around week 4 and declining sharply by week 8; CD68-positive macrophages (immune phagocytes identified by the CD68 surface marker) were transiently more abundant at day 10 but reduced at weeks 4 and 8; and CD34-positive cells (labeled by CD34, a marker of blood-vessel endothelium and of hematopoietic and endothelial progenitors) and typical blood vessels were most prominent in the SDF-1α group. In a rabbit radial segmental defect model, the SDF-1α/Col/HA scaffold significantly improved bone regeneration at 1 and 2 months. The in vitro release profile lasted 49 days (about 20.5% burst release in the first 12 hours; about 83.6% cumulative release by day 49), and the authors attributed the week-8 decline in MSC-marker-positive cells to the waning of SDF-1α release, noting verbatim that 'the exact origin of MSCs is still debated'. Mechanistic explanations for the macrophage and vessel findings were explicitly speculative. Follow-up work has advanced the release-technology side: gene-activated scaffolds carrying an SDF-1α plasmid sustain local SDF-1α expression and accelerate repair of critical-sized calvarial defects (Raftery et al., 2024), and nanoparticle-hydrogel systems achieve sustained dual-factor release of SDF-1α with osteoprotegerin, macrophage M2-polarization (a pro-regenerative macrophage phenotype), and improved femoral defect healing (Jiao et al., 2025). Separately, fate-mapping studies of natural fracture healing have identified periosteal skeletal stem and progenitor cells as the dominant cellular origin of healed bone in mice (Liu et al., 2024; Xing et al., 2024) — but no equivalent lineage-tracing, parabiosis, or chimera study has determined the source of the MSC-like cells that populate SDF-1α-presenting implanted scaffolds, and reviews of chemokine-based bone and cartilage engineering continue to list controlled release and the biological pathways of chemotactic factors as open challenges (Chen, Gao and Yao, 2022; Xia, Deng, Lv and Chen, 2021).

Problem Statement

For bone-regeneration scaffolds that present SDF-1α on a mechanically tuned, decellularized matrix to recruit endogenous cells in situ, determine the three linked unknowns that decide whether endogenous recruitment can substitute mechanistically and controllably for cell transplantation: (1) the cellular origin of the recruited MSC-like cells — specifically, whether the CD29/CD44/CD90/CD105-positive cells that populate the implanted scaffold derive from locally resident progenitors at the implant site (e.g., periosteum, endosteum, or adjacent marrow), from cells delivered through the systemic circulation (e.g., bone-marrow-derived cells mobilized into the blood), or from other niches; the source identifies these cells only by marker immunostaining, and direct tracking approaches — for example genetic fate mapping (irreversibly labeling a defined cell population and all of its descendants), parabiosis (surgically joining two animals so that they share a bloodstream, which separates circulating from local sources), or bone-marrow chimeras (animals whose blood and marrow cells have been replaced by labeled donor cells) — are candidate routes to a determination; (2) how SDF-1α presentation can be potentiated and prolonged — in dose, duration, or release strategy — so that endogenous recruitment is sustained rather than declining as chemokine release wanes; and (3) the mechanisms underlying the observed host responses to the scaffold — the transient day-10 increase of CD68-positive macrophages followed by reduced accumulation at weeks 4 and 8, and the enhanced CD34-positive cell and vessel formation — for which the source offers only explicitly speculative explanations ('may contribute to the reduced accumulation of inflammatory cells'; 'SDF-1α may magnify the vessel formation ability ... may involve in attracting of CD34-positive hematopoietic stem cells and endothelial progenitor cells'); the answer must be a causal account — a ranked set of candidate mechanisms, each paired with the experiments that would discriminate it from the others — of how the scaffold's SDF-1α presentation and matrix elasticity act through the recruited cells to produce these responses. The three parts are jointly required: a complete answer must address all three together, and a determination of any single part does not by itself resolve the task; each part is to be interpreted within the common objective of making endogenous-cell recruitment for bone regeneration mechanistically understood and designable.

References

  1. Guobao Chen, Yonggang Lv. Matrix elasticity-modified scaffold loaded with SDF-1α improves the in situ regeneration of segmental bone defect in rabbit radius. Scientific Reports 7:1672 (2017). DOI: 10.1038/s41598-017-01938-3. https://doi.org/10.1038/s41598-017-01938-3
  2. Bin Xia, Yaxin Deng, Yonggang Lv, Guobao Chen. Stem cell recruitment based on scaffold features for bone tissue engineering. Biomaterials Science 9:1189–1203 (2021). DOI: 10.1039/d0bm01591a. https://doi.org/10.1039/d0bm01591a
  3. R. M. Raftery, A. G. Gonzalez Vazquez, D. P. Walsh, G. Chen, A. L. Laiva, M. B. Keogh, F. J. O'Brien. Mobilizing endogenous progenitor cells using pSDF1α-activated scaffolds accelerates angiogenesis and bone repair in critical-sized bone defects. Advanced Healthcare Materials 13(23):e2401031 (2024). DOI: 10.1002/adhm.202401031. https://doi.org/10.1002/adhm.202401031
  4. Y. Jiao, H. Wang, M. Zhao, H. Liu, P. Shen, G. Wu, T. Forouzanfar, F. R. Tay, L. Miao, H. Liu, Q. Liu. Multifunctional nanocomposite hydrogel with dual-factor controlled release for stem cell recruitment, immunomodulation and bone remodeling. Journal of Controlled Release 384:113893 (2025). DOI: 10.1016/j.jconrel.2025.113893. https://doi.org/10.1016/j.jconrel.2025.113893
  5. Ke Chen, Hui Gao, Yongchang Yao. Prospects of cell chemotactic factors in bone and cartilage tissue engineering. Expert Opinion on Biological Therapy 22(7):883–893 (2022). DOI: 10.1080/14712598.2022.2087471. https://doi.org/10.1080/14712598.2022.2087471
  6. Yuqiang Wang, Ziyan Zhang, Xuedi Sun, Chengdong Piao. Recent progress in immunomodulation-based strategies for bone repair. Regenerative Therapy 31:101054 (2026; published online December 2025). DOI: 10.1016/j.reth.2025.101054. https://doi.org/10.1016/j.reth.2025.101054
  7. Y. L. Liu, X. T. Tang, H. S. Shu, W. Zou, B. O. Zhou. Fibrous periosteum repairs bone fracture and maintains the healed bone throughout mouse adulthood. Developmental Cell 59(9):1192–1209.e6 (2024). DOI: 10.1016/j.devcel.2024.03.019. https://doi.org/10.1016/j.devcel.2024.03.019
  8. W. Xing, H. Feng, B. Jiang, B. Gao, J. Liu, Z. Xie, Y. Zhang, X. Hu, J. Sun, M. B. Greenblatt, B. O. Zhou, W. Zou. Itm2a expression marks periosteal skeletal stem cells that contribute to bone fracture healing. Journal of Clinical Investigation 134(17):e176528 (2024). DOI: 10.1172/JCI176528. https://doi.org/10.1172/JCI176528
  9. T. Li, M. Peng, Z. Yang, X. Zhou, Y. Deng, C. Jiang, M. Xiao, J. Wang. 3D-printed IFN-γ-loading calcium silicate-β-tricalcium phosphate scaffold sequentially activates M1 and M2 polarization of macrophages to promote vascularization of tissue engineering bone. Acta Biomaterialia 71:96–107 (2018). DOI: 10.1016/j.actbio.2018.03.012. https://doi.org/10.1016/j.actbio.2018.03.012